LYMPHOMA
RESEARCH • FOUNDATION

FOR IMMEDIATE RELEASE
September 7, 2016

Contact
Jake DiGregorio 508-414-8853
jdigregorio@lymphoma.org

Lymphoma Research Foundation Statement on the U.S. Food and Drug Administration Approval of Ofatumumab (Arzerra ®) for Chronic Lymphocytic Leukemia

New York, NY – On August 31, the U.S. Food and Drug Administration (FDA) announced it has approved the use of ofatumumab (Arzerra ®) to treat patients with relapsed chronic lymphocytic leukemia (CLL) in combination with fludarabine and cyclophosphamide. This announcement marks the fourth Supplemental Biologics License Application approval for the drug.

"The most recent approval of ofatumumab results not only in an expansion of treatment options for people with CLL, but is also representative of the progress being made in the field of lymphoma and CLL research," said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation.

Ofatumumab was previously approved by the FDA for the treatment of previously untreated patients with CLL not eligible to receive fludarabine-based therapy, patients with CLL refractory to fludarabine and alemtuzumab, and patients with recurrent or progressive chronic lymphocytic leukemia (CLL) who are in complete or partial response after at least two lines of therapy. For additional information on the approval of ofatumumab, visit http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125326s063lbl.pdf

For additional information on chronic lymphocytic leukemia, visit www.focusoncll.org.

About the Lymphoma Research Foundation
The Lymphoma Research Foundation (LRF) is the nation's largest non-profit organization devoted to funding innovative research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives and patient services. To date, LRF has awarded nearly $58 million in lymphoma-specific research. For additional information on LRF's research, education and services, visit lymphoma.org.

###